Cobenfy

3D Rendering futuristic robot technology development artificial intelligence
Biotech

MapLight illuminates $262M IPO plans to fund Cobenfy competitor

MapLight is hoping to raise up to $262 million from its IPO, with the proceeds earmarked for its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy.
James Waldron Oct 7, 2025 6:30am
Boerner
Favicon Fierce Pharma

BMS touts commercial execution, reckons with clinical setbacks

Jul 31, 2025 11:10am